Fulcrum Therapeutics (FULC) Receivables - Other (2020 - 2025)

Fulcrum Therapeutics (FULC) has 6 years of Receivables - Other data on file, last reported at $979000.0 in Q1 2025.

• On a quarterly basis, Receivables - Other changed N/A year-over-year to $979000.0 in Q1 2025; TTM through Mar 2025 was $979000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $2.1 million, up 290.32% from the prior year.
• Receivables - Other for Q1 2025 stood at $979000.0, down from $2.1 million in the prior quarter.
• Over the last five years, Receivables - Other for FULC reached as high as $3.7 million in Q3 2024 and fell as low as $99000.0 in Q1 2023.
• Historically, Receivables - Other has averaged $1.1 million across 5 years, with a median of $766500.0 in 2022.
• Across the five-year window, Receivables - Other slumped 87.66% in 2023 and surged 530.34% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $1.1 million in 2021, then sank by 79.86% to $229000.0 in 2022, then soared by 134.5% to $537000.0 in 2023, then jumped by 290.32% to $2.1 million in 2024, then slumped by 53.29% to $979000.0 in 2025.
• Per Business Quant data, the three most recent Receivables - Other figures were $979000.0 in Q1 2025, $2.1 million in Q4 2024, and $3.7 million in Q3 2024.